The cells provided in this description include immunotherapy consisting of chemically antigen receptor genetically altered lymphocytes and autistic cells for the treatment of lymphocyte B with recurrence or high fire resistance after two or more systemic treatment lines. Diffuse lymphoma including large B lymphoma (dbcl) (not otherwise specified), intermediate lymphoma of large B lymphoma,High concentration B lymphoma and dbcl lymphoma come from lymphoma Some aspects of the note relate to treatment and monitoring methods currently available after injection of T-lymphocyte therapy. A method for the treatment of diffuse lymphoma or large Recife or refractory lymphoid (dbcl), which is not specified in other ways, is the main intermediate Lymphoid Lymphoma B large lymphoma, Grade II or above lymphoma B or dbcl lymphoma is a lymphoma arising from lymphoma. Two or more systems of treatment have been carried out in one patient, including clinical and clinical treatment of patients in need of treatmenta. The dose of viable T lymphocytes per kg body weight ranged from 1 ′ 108310a to 2 ′ 1083100e, and the highest dose was 1 ′ 10831222；Here, the cylindrical axis is an immunotherapy with genetically modified CD19 lymphocytes and autistic cells, including T lymphocytes collected from patients themselves, that are genetically modified by an antiretroviral converter to express a chemical antigen receptor (car), which includes a fragment Anti CD19 single chain variable (scFv) is the common host domain of CD28 and cd3-z.La descripción proporciona células que comprenden una inmunoterapia con linfocitos T autólogos modificados genéticamente del receptor de antígeno quimérico (CAR) dirigidos a CD19 para el tratamiento de, por ejemplo, linfoma de linfocitos B grandes recidivante o refractario luego de dos o más líneas de terapia sistémica, que incluyen linfoma difuso de linfocitos B grandes (DLBCL) no especificado de otra forma, linfoma primario mediastinal de linfocitos B grandes, linf
